¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gene mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • spontaneous mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • suppressor mutation
    ¾ïÁ¦(µ¹¿¬)º¯ÀÌ
  • temperature-sensitive mutation
    ¿Âµµ¹Î°¨µ¹¿¬º¯ÀÌ
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • reversible mutation
    µÇÁý±âµ¹¿¬º¯ÀÌ, °¡¿ªµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • spontaneous mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • suppression mutation
    ¾ïÁ¦µ¹¿¬º¯ÀÌ
  • temperature-sensitive mutation
    ¿Âµµ¹Î°¨µ¹¿¬º¯ÀÌ
  • voice mutation
    º¯¼º
  • somatic mutation theory
    ü¼¼Æ÷µ¹¿¬º¯À̼³
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene amplification
    À¯ÀüÀÚ ÁõÆø
  • gene analyses
    À¯ÀüÀںм®
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯.
  • gene conversion
    À¯ÀüÀÚº¯È¯(ܨüµ).
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ.
  • gene defect
    À¯ÀüÀÚ°á¼Õ<--°á¿©>
  • gene deletion
    À¯ÀüÀÚ°á½Ç<--»èÁ¦
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • gene, operator
    ÀÛµ¿À¯ÀüÀÚ
  • gene, regulatory
    Á¶ÀýÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mutation, forward
    ÀüÇâ µ¹¿¬º¯ÀÌ
  • mutation, frame-shift
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • mutation, missense
    °ú¿À µ¹¿¬º¯ÀÌ, ¹Ì¼¾½º µ¹¿¬º¯ÀÌ
  • mutation, nonsense
    ¹«ÀÇ¹Ì µ¹¿¬º¯ÀÌ, ³­¼¾½º µ¹¿¬º¯ÀÌ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • mutation, point
    Á¡ µ¹¿¬º¯ÀÌ
  • mutation, polar
    ±Ø¼ºÈ¿°ú°¡ ³ª´Âµ¹¿¬º¯ÀÌ
  • mutation, reading frame
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ
  • mutation, recessive
    ¿­¼º µ¹¿¬º¯ÀÌ
  • mutation, reversible
    °¡¿ª¼º µ¹¿¬º¯ÀÌ
  • mutation, somatic
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • mutation, spontaneous
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • mutation, suppressor
    ¾ïÁ¦ µ¹¿¬º¯ÀÌ (¹ßÇö)
  • natural mutation
    ÀÚ¿¬(µ¹¿¬)º¯ÀÌ(~ÔÍæÔܨì¶).
  • nonsense mutation
    ³­¼¾½º(µ¹¿¬)º¯ÀÌ(~ÔÍæÔܨì¶).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • point mutation
    Á¡º¯ÀÌ(ïÃܨì¶)
  • polarity mutation
    ±Ø¼º º¯ÀÌ(пàõܨì¶)
  • polar mutation
    ±Ø¼º º¯ÀÌ(пàõܨì¶)
  • promoter-down mutation
    ÇÁ·Î¸ðÅÍ ±â´ÉÀúÇÏ º¯ÀÌ(ѦÒöî¸ù»Ü¨ì¶)
  • promoter mutation
    ÇÁ·Î¸ðÅÍ º¯ÀÌ(ܨì¶)
  • promoter-up mutation
    ÇÁ·Î¸ðÅÍ ±â´É»ó½Âº¯ÀÌ(ѦÒöß¾ã°Ü¨ì¶)
  • Quaking mutation
    ÄùÀÌÅ· º¯ÀÌ(ܨì¶).
  • samesense mutation
    µ¿ÀÇ º¯ÀÌ(ÔÒëòܨì¶)
  • second-site mutation
    µÑ° ÀÚ¸® º¯ÀÌ(ܨì¶)
  • semilethal mutation
    ÁØÄ¡»ç º¯ÀÌ(ñÞöÈÞÝܨì¶)
  • sign mutation
    ½ÅÈ£º¯ÀÌ(ãáûÜܨì¶)
  • silent mutation
    ħ¹¬ º¯ÀÌ(öØÙùܨì¶)
  • single-site mutation
    ¿ÜÀÚ¸® º¯ÀÌ(ܨì¶)
  • somatic mutation
    ü¼¼Æ÷ º¯ÀÌ(ô÷á¬øàܨì¶)
  • somatic mutation theory
    ü¼¼Æ÷ º¯ÀÌÀÌ·Ð(ô÷á¬øàܨì¶×âÖå)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CGRP calcitonin gene-related peptide
cGRP calcitonin gene-related peptide
CGRPR calcitonin gene related peptide receptor
che a gene involved in chemotaxis
CMGT chromosome-mediated gene transfer
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CGRP AM/calcitonin gene-related peptide
alpha-CGRP Alpha calcitonin gene-related peptide
APO E Apolipoprotein E gene
CGRP CT gene-related peptide
CGRP-LI Calcitonin gene related peptide-like immunoreactivity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
  • mutator gene
    º¯ÀÌ À¯¹ß À¯ÀüÀÚ
  • nucleolar gene
    ÇÙ ¼Òü À¯ÀüÀÚ
  • operator gene
    ÀÛµ¿ À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
    ¿­¼º ÈÄÅð ¶Ç´Â ÇÔ¿äÇϱ⠽¬¿î °Í. Áö¹è·ÂÀ» ³ªÅ¸³»Áö ¸øÇϰųª ¿µÇâ·ÂÀ» ÅëÁ¦ÇÏÁö ¸øÇÏ´Â °Í. À¯ÀüÇп¡¼­´Â ´ë¸³ À¯ÀüÀÚ°¡ »óµ¿ ¿°»öü »ó¿¡ ¾øÀ¸¸é ÇüÁúÀ» ¹ßÇöÇÏÁö ¸øÇÏ´Â °Í.
  • regulator gene
    Á¶Àý À¯ÀüÀÚ
  • regulatory gene
    Á¶Àý À¯ÀüÀÚ
  • structural gene
    ±¸Á¶ À¯ÀüÀÚ
  • virulence gene
    µ¶¼º À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
suppressor mutation <molecular biology> Mutation that alleviates the effect of a primary mutation at a different locus.
May be through almost any mechanism that can give a primary mutation, but perhaps the most interesting class are the amber and ochre supressors, where the anticodon of the tRNA is altered so that it mis reads the termination codon and inserts an amino acid, preventing premature termination of the peptide chain.
(18 Nov 1997)
deletion mutation <molecular biology> A mutation in which one or more (sequential) nucleotides is lost by the genome. If the number lost is not divisible by 3 and is in a coding region, the result is a frameshift mutation.
(18 Nov 1997)
down promoter mutation <molecular biology> A mutation (a change in base pair sequence) in a promoter region, this results in lower gene expression (less transcription of the gene occurs).
(09 Oct 1997)
induced mutation A mutation caused by exposure to a mutagen.
(05 Mar 2000)
insertion mutation A mutation caused by the insertion of at least one extra nucleotide basein a DNA sequence.
(09 Oct 1997)
ochre mutation Mutation that changes any codon to the termination codon UAA.
(18 Nov 1997)
opal mutation <molecular biology> Mutation that changes any codon to the termination codon UGA.
(18 Nov 1997)
temperature sensitive mutation <genetics, molecular biology> A type of conditional mutation in organism, somatic cell or virus that makes it possible to study genes whose total inactivation would be lethal. Such ts mutations can also make possible studies of the effect of reversible switching by temperature changes) in expression of the mutated gene. The usual mechanism of temperature sensitivity is that the mutated gene codes for a protein with a temperature dependent conformational instability, so that it possesses normal activity at one temperature (the permissive temperature), but is inactive at a second (nonpermissive) temperature.
(18 Nov 1997)
transition mutation A point mutation involving substitution of one base-pair for another, i.e., replacement of one purine for another and of one pyrimidine for another pyrimidine without change in the purine-pyrimidine orientation.
(05 Mar 2000)
transversion mutation A point mutation involving base substitution in which the orientation of purine and pyrimidine is reversed, in contradistinction to transition mutation.
(05 Mar 2000)
umber mutation A mutation yielding the termination codon UGA, resulting in premature termination of a polypeptide chain.
Compare: suppressor mutation.
Synonym: opal mutation.
(05 Mar 2000)
unstable mutation <molecular biology> A mutation that has a high likelihood of reverting to its original form.
(13 Nov 1997)
up mutation <molecular biology> Refers to any mutation in the promoter region of a gene which can trigger transcription initiation.
(09 Oct 1997)
up promoter mutation A mutation that increases the frequency of initiation of transcription.
(05 Mar 2000)
forward mutation Any mutation which renders a formerly functional gene nonfunctional.
Compare: back mutation.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á